Jun.28,2007  9  US 2007/0148124 Al  prodrug, as described herein, or the cellulose based polymer  or pharmaceutically acceptable salt thereof or prodrug or  combination of any of the foregoing in therapeutically or  prophylatically effective amounts, respectively.  [0079]  The present invention is also directed to a pharma› ceutical composition comprising a therapeutically effective  amount of an anionic cellulose-based polymer or a pharma› ceutically acceptable salt thereof or prodrug thereof or an  anionic acrylic-based polymer or pharmaceutically accept› able salt thereof or a prodrug thereof or a combination  thereof in association with a pharmaceutically acceptable  carrier, vehicle, or diluent.  [0080]  The present invention is also directed to polymers  having repeating units of Formula I or II, as described herein  or pharmaceutically acceptable salts of polymers of Formula  I or II or prodrugs of polymers of Formula I or II for the  utility described herein.  [0081]  The present invention also provides pharmaceuti› cal compositions comprising a therapeutically effective  amount of the anionic cellulose-based polymer or the  anionic acrylic-based polymer described herein, a prodrug  of either said anionic cellulose-based polymer or anionic  acrylic-based polymer, or a combination thereof or a phar› maceutically acceptable salt of said anionic cellulose based  polymer or acrylic-based polymer or prodrug; and a phar› maceutically acceptable carrier, vehicle or diluent. The  pharmaceutical compositions can be delivered in a liquid or  solid dosage form. Alternatively, the pharmaceutical com› positions can be incorporated into barrier devices such as  condoms, diaphragms, or cervical caps. The pharmaceutical  compositions described herein are useful for the treatment of  a virus, bacterial, or fungal infection in a host.  [0082]  The present invention also provides methods for  the treatment or prevention of a virus, bacterial, or fungal  infection in a host, which comprises administering to the  host a therapeutically effective amount of an anionic cellu› lose-based polymer, a prodrug thereof, or a pharmaceuti› cally acceptable salt of said anionic cellulose-based polymer  or prodrug in combination with one or more anti-infective  agents. More particularly, the one or more anti-infective  agents can be an anti-viral agent, an anti-bacterial agent, an  anti-fungal agent, or a combination thereof. Further, the  anionic cellulose-based polymer and the one or more anti› infective agents can be administered simultaneously or  sequentially.  [0083]  In another embodiment, said one or more anti› infective agents in such methods include antiviral protease  enzyme inhibitors (PI), virus DNA or RNA or reverse  transcriptase (RT) polymerase inhibitors, virus/cell fusion  inhibitors, virus integrase enzyme inhibitors, virus/cell bind› ing inhibitors, and/or virus or cell helicase enzyme inhibi› tors, bacterial cell wall biosynthesis inhibitors, virus or  bacterial attachment inhibitors, HIV-1 RT inhibitors (such as  Tenofovir, epivir, zidovudine, or stavudine, and the like),  HIV-1 protease inhibitors ( such as saquinavir, ritonavir,  nelfmavir,  indinavir,  amprenavir,  lopinavir,  atazanavir,  tipranavir, fosamprenavir, and the like), HIV-1 fusion inhibi› tors (such as Fuzeon (T20), or PRO-542, SCH-C, and the  like), polybiguanides (PBGs ), herpes virus DNA polymerase  inhibitors (such as acyclovir, ganciclovir, cidofovir, and the  like), herpes virus protease inhibitors, herpes virus fusion  inhibitors, herpes virus binding inhibitors, and ribonucle› otide reductase inhibitors.  [0084]  The present invention also provides methods for  the treatment or prevention of a virus, bacterial, or fungal  infection in a host, which comprises administering to the  host a therapeutically effective amount of an anionic acrylic  based polymer, a prodrug thereof, or a pharmaceutically  acceptable salt of said anionic acrylic based polymer or  prodrug in combination with one or more anti-infective  agents. More particularly, the one or more anti-infective  agents can be an anti-viral agent, an anti-bacterial agent, an  anti-fingal agent, or combination thereof. More particularly,  the anionic acrylic based polymer and the one or more  anti-infective agents can be administered simultaneously or  sequentially.  [0085]  In another embodiment, said one or more anti› infective agents of such methods include antiviral protease  enzyme inhibitors (PI), virus DNA or RNA or reverse  transcriptase (RT) polymerase inhibitors, virus/cell fusion  inhibitors, virus integrase enzyme inhibitors, virus/cell bind› ing inhibitors, and/or virus or cell helicase enzyme inhibi› tors, bacterial cell wall biosynthesis inhibitors, virus or  bacterial attachment inhibitors, HIV-1 RT inhibitors (such as  Tenofovir, epivir, zidovudine, or stavudine, and the like),  HIV-1 protease inhibitors ( such as saquinavir, ritonavir,  nelfmavir,  indinavir,  amprenavir,  lopinavir,  atazanavir,  tipranavir, fosamprenavir, and the like), HIV-1 fusion inhibi› tors (such as Fuzeon (T20), or PRO-542, SCH-C, and the  like), polybiguanides (PBGs ), herpes virus DNA polymerase  inhibitors (such as acyclovir, ganciclovir, cidofovir, and the  like), herpes virus protease inhibitors, herpes virus fusion  inhibitors, herpes virus binding inhibitors, and ribonucle› otide reductase inhibitors.  [0086]  The present invention also provides pharmaceuti› cal combination compositions comprising a therapeutically  effective amount of a composition which comprises a thera› peutically effective amount of an anionic cellulose-based  polymer, a prodrug of said anionic cellulose based polymer,  or a pharmaceutically acceptable salt of said anionic cellu› lose-based polymer or prodrug; one or more anti-infective  agents; and a pharmaceutically acceptable carrier, vehicle or  diluent.  [0087]  In another embodiment, said one or more anti› infective agents in such pharmaceutical combination com› positions include antiviral protease enzyme inhibitors (PI),  virus DNA or RNA or reverse transcriptase (RT) polymerase  inhibitors,  virus/cell fusion inhibitors, virus integrase  enzyme inhibitors, virus/cell binding inhibitors, and/or virus  or cell helicase enzyme inhibitors, bacterial cell wall bio› synthesis inhibitors, virus or bacterial attachment inhibitors,  HIV-1 RT inhibitors (such as Tenofovir, epivir, zidovudine,  or stavudine, and the like), HIV-1 protease inhibitors (such  as saquinavir, ritonavir, nelfinavir, indinavir, amprenavir,  lopinavir, atazanavir, tipranavir, fosamprenavir, and the  like), HIV-1 fusion inhibitors (such as Fuzeon (T20), or  PRO-542, SCH-C, and the like), polybiguanides (PBGs),  herpes virus DNA polymerase inhibitors ( such as acyclovir,  ganciclovir, cidofovir, and the like), herpes virus protease  inhibitors, herpes virus fusion inhibitors, herpes virus bind› ing inhibitors, and ribonucleotide reductase inhibitors.  [0088]  The present invention also provides pharmaceuti› cal combination compositions comprising a therapeutically  effective amount of a composition which comprises a thera› peutically effective amount of an anionic acrylic-based  polymer, a prodrug of said anionic acrylic-based polymer, or 